









Markets
/
Stocks
/
nasdaq-rlmd
/

Relmada Therapeutics Inc

RLMD

1.530USD

-0.120-7.27%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

50.78MMarket Cap

LossP/E TTM



Relmada Therapeutics Inc

1.530

-0.120-7.27%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

152 / 506

Overall Ranking

261 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Hold

Current Rating

1.000

Target Price

-39.39%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.

Fairly Valued

The company’s latest PE is -0.70, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 17.22M shares, decreasing 8.11% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 364.08K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.76.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.49, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.49

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.75, which is -28.27% below the recent high of -0.54 and -30.14% above the recent low of -0.98.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 152/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 6.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Relmada Therapeutics Inc is 1.00, with a high of 1.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Hold

Current Rating

1.000

Target Price

-39.39%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Relmada Therapeutics Inc

RLMD

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.93, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.19 and the support level at 0.85, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.93

Change

-0.17

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.006

Neutral

RSI(14)

62.764

Neutral

STOCH(KDJ)(9,3,3)

32.754

Sell

ATR(14)

0.270

Low Volatility

CCI(14)

34.303

Neutral

Williams %R

46.261

Neutral

TRIX(12,20)

4.028

Buy

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.592

Sell

MA10

1.584

Sell

MA20

1.311

Buy

MA50

0.894

Buy

MA100

0.741

Buy

MA200

0.574

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 51.89%, representing a quarter-over-quarter increase of 16.98%. The largest institutional shareholder is The Vanguard, holding a total of 364.08K shares, representing 1.10% of shares outstanding, with 73.66% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Trigone Pharma Ltd

3.02M

VR Adviser, LLC

2.27M

Kotler (Kevin)

1.90M

Traversa (Sergio)

734.02K

+91.14%

Acadian Asset Management LLC

1.23M

BlackRock Institutional Trust Company, N.A.

562.21K

-0.59%

Kelly (Paul Edward)

412.30K

+94.21%

AdvisorShares Investments, LLC

276.51K

+31.63%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.95, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.80. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.